AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • March 11th, 2011 • Orexigen Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”) is entered into as of the 6th day of December, 2010 (the “A&R Effective Date”) by and between GlaxoSmithKline LLC (formerly known as SmithKline Beecham Corporation, doing business as GlaxoSmithKline), a Delaware limited liability company located at One Franklin Plaza, Philadelphia, PA 19102 (“GSK LLC”), Glaxo Group Limited, a private limited company incorporated in England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, England UB6 0NN (“GGL,” and together with GSK LLC, “GSK”) and Orexigen Therapeutics, Inc., a Delaware corporation located at 3344 N. Torrey Pines Court, Suite 200, La Jolla, California 92037 (“Orexigen”). GSK and Orexigen are sometimes collectively referred to herein as the “Parties” and separately as a “Party.”
